Safety and Efficacy of Rasagiline in Restless Legs Syndrome

Inclusion Criteria: * Men and women at least 18 years of age, capable of providing informed consent * Diagnosed with idiopathic RLS, defined as meeting the International RLS Study Group diagnostic criteria without evidence for secondary causes of RLS * Moderate or severe symptoms, defined as a score of 15 or greater on the International RLS Study Group Rating Scale (IRLS) * Not currently receiving treatment for RLS. A 30-day washout period will be required for participants on dopamine agonists or other therapies. Stable doses of iron supplementation will be allowed * On a stable dose of the following antidepressants, for at least 30 days prior to baseline visit: * Amitriptyline, up to 50mg/day * Trazodone, up to 100mg/day * Citalopram, up to 20mg/day * Escitalopram, up to 10mg/day * Paroxetine, up to 30mg/day * Sertraline, up to 100mg/day * Female subjects must not be of childbearing potential or must agree to use of contraception for duration of study Exclusion Criteria: * Signs consistent with a secondary cause of RLS: * History of initial unresponsiveness to dopaminergic RLS treatment despite adequate dose of initial therapy * Use of another MAO inhibitor within 30 days of baseline visit * Allergy or adverse reaction to rasagiline * Prior adverse reaction to tyramine-containing foods * Use of meperidine or other opiates within 30 days of the baseline visit * Use of benzodiazepines within 30 days of the baseline visit * Use of antidepressants, including TCAs, SSRIs, and SNRIs, except for those permitted as listed above * Use of other drugs or supplements contraindicated with rasagiline, including St. John's wort, mirtazapine, cyclobenzaprine, dextromethorphan, cold products that contain ephedrine, pseudoephedrine * Scheduled to undergo elective surgery during the course of the study * Active medical or psychiatric illness that requires changes to treatment during the course of the study or jeopardize the subject's ability to remain in the study